<DOC>
	<DOCNO>NCT02448979</DOCNO>
	<brief_summary>Esophageal carcinoma aggressive malignant disease poor prognosis . Surgical resection remain effective method malignancy . Although different approach study surgical resection thoracic esophageal cancer , little evidence achieve due lack large scale multicenter randomize trial regard issue : whether leave transthoracic approach right transthoracic approach optimal surgical approach treat middle low thoracic esophageal cancer without upper mediastinal lymph node metastasis . The purpose study compare postoperative local recurrence rate long-term outcome esophagectomy leave right transthoracic approach middle low thoracic esophageal cancer patient without preoperative upper mediastinal lymph node metastasis .</brief_summary>
	<brief_title>Esophagectomy Middle Lower Thoracic Esophageal Cancer Patients Through Left Versus Right Transthoracic Approach</brief_title>
	<detailed_description>Esophageal carcinoma aggressive malignant disease poor prognosis . Surgical resection remain effective method malignancy . As middle low thoracic esophageal cancer patient without upper mediastinal lymph node metastasis , rational transthoracic approach either right leave chest clarified date due lack large scale multicenter randomize trial . Although randomized trial finish single-center , enough evidence low middle thoracic esophageal cancer patient surgically treat throuhg right chest approch . It widely recognize left thoracotomy approach ( Sweet procedure ) appropriate patient upper mediastinal lymph node metastasis , patient benefit right thoracotomy approach , upper mediastinal lymph node dissect completely may get good long-term survival.Therefore , study , enrol patient middle low thoracic esophageal cancer patient without preoperative upper mediastinal lymph node metastasis CT and/or ultrasound , 10 hospital participate study . Through comparison postoperative complication long term outcomes well locoregional recurrence leave right apppoach , hopefully answer question whether right leave transthoracic procedure optimal approach treat middle low thoracic esophageal cancer patient without preoperative upper mediastinal lymph node metastasis .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Patients histologically prove squamous cell esophageal cancer without previous antitumor therapy ; 2 . The preoperative clinical TNM stage : cT1b3N01M0 ; 3 . Adequate function heart , lung , liver , brain kidney , tolerate esophagectomy either leave right thoracotomy ; 4 . Without preoperative distant metastasis confirm preoperative examination chest abdominal CT , brain MRI bone scan PETCT ; 5 . No evidence show suspicious upper mediastinal lymph node metastasis ( short diameter LN &lt; 0.8cm shortest diameter / long diameter &lt; 0.65 ) thoracic abdominal CT endoscopic ultrasonography ( EUS ) . 6 . Willing participate clinical trial sign inform consent enrol clinical trail . 1 . Nonsquamous cell esophageal carcinoma previous anticancer therapy surgery ; 2 . The preoperative clinical TNM stage reach : N23 M1 ; 3 . Inadequate cardiopulmonary , liver , brain kidney function tolerate esophagectomy ; 4 . Previous history malignancy ; 5 . Unwilling participate clinical trial refuse sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>